Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

Inclusion Criteria: * Male or female participants between the ages of 18 and 55 years. * Participants considered 'healthy' to be eligible for study participation. * Participants who are willing and able to comply with all scheduled visits and other study procedures. * Participants with Body mass index (BMI) within the normal range. * Participants with deltoid muscle capable of IP injection. * Those that agreed to using medically approved contraception. * Female participants with potential pregnancy- Those that used medically approved contraception and has negative result at the pregnancy test. * Capable of giving personal signed informed consent Exclusion Criteria: * Clinically significant symptoms prior to IP injection. * Confirmed to be COVID-19 RT-PCR positive or to have made close contact with SARS-CoV-2 infected patient. * History of virologically-confirmed SARS, MERS, or COVID-19. * History of congenital or acquired immunodeficiency or autoimmune diseases. * Positive result of hepatitis B, C, RPR test, or HIV. * History of disorder that inhibits intramuscular injection of the vaccine. * History of hypersensitivity and severe allergic reaction to any of the components of IP. * History of malignant tumor within 5 years prior to the first IP injection. * Clinically significant chronic diseases that could cause safety concerns regarding COVID-19. * Scheduled of , or history of surgery under general anaesthesia prior to first IP injection, * Female participant that is pregnant or is currently breastfeeding. * Smoker or history of smoking within 12 weeks prior to first IP injection. * Previous vaccination or treatment for prevention of COVID-19. * Vaccination prior to the first IP injection or scheduled of vaccination after second IP injection. * Treated with immunoglobulin and/or blood/blood components prior to first IP injection. * Chronic use of immunosuppressant prior to first IP injection. * Participated in other clinical study prior to first IP injection, or scheduled to participate in other study during the study period. * Healthcare worker or emergency response personnel. * Conditions that may influence the evaluation of the study objectives.